Efficacy and toxicity profile of eribulin mesylate for metastatic breast cancer (MBC) patients (pts) in the routine clinic: A French observational study

Authors :: Jerome Martin
Anne Patsouris
Adele Marquis
Olivier Tredan
Benjamin Linot
Herve Desclos
Hugues Bourgeois
Carole Gourmelon
C. Lefeuvre-Plesse
Marie Robert
Mickael Som
Angélique Brunot
Mario Campone
Source :: Journal of Clinical Oncology. 32:e11555-e11555
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e11555 Background: In the EMBRACE Phase III trial of heavily pretreated patients (pts) with metastatic breast cancer (MBC), eribulin, a microtubule dynamics inhibitor, has demonstrated a statistica...

Subjects :: Eribulin Mesylate
Oncology
Cancer Research
medicine.medical_specialty
Microtubule dynamics
business.industry
Pharmacology
medicine.disease
Metastatic breast cancer
chemistry.chemical_compound
chemistry
Internal medicine
medicine
bacteria
Observational study
skin and connective tissue diseases
business
Toxicity profile
Eribulin

Tools